hotspot -WSS

hotspot

author：comprehensive 2025-09-28 02:29:10 - browse：998

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Just how do doctors, lawmakers, and the public define abortion?

WSS

What to know about Saharan dust affecting the US and how it can affect health

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Providers still hesitate to prescribe buprenorphine, study finds

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Organ transplantation is at a crossroads. Major reform is needed

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

HIPAA doesn't protect reproductive records from prosecutors

Activists slam private health insurers over coverage restrictions

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

State Dept. review finds Biden bears some blame for Afghanistan failures

The drug industry has found itself all alone in Washington

Tori Bowie and the unacceptable rates of Black maternal death

UnitedHealth quietly bought dozens of outpatient centers

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Caitlin Bernard's story shows physicians can't shy from advocacy

focus

The problem with charging patients to message their doctors

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

AbbVie dramatically boosts its spending on lobbying

Marvel Studios reveals new trailer for 'The Marvels': Watch here

With psoriasis trial ahead, Alumis raises $259 million

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

focus

hotspot

knowledge

Wikipedia